GENMAB Inactive Instrument
Genmab Stock Nasdaq Copenhagen
Equities
DK0010272202
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,076 DKK | +70.58% |
|
+4.14% | +14.24% |
| Apr. 11 | Health Care Slips on Risk Bias -- Health Care Roundup | DJ |
| Apr. 03 | Health Care Flat on Rotation to Rate-Sensitive Sectors -- Health Care Roundup | DJ |
| Sales 2024 * | 19.63B 2.8B | Sales 2025 * | 23.5B 3.35B | Capitalization | 134B 19.06B |
|---|---|---|---|---|---|
| Net income 2024 * | 5.07B 723M | Net income 2025 * | 6.64B 946M | EV / Sales 2024 * | 5.42 x |
| Net cash position 2024 * | 27.34B 3.9B | Net cash position 2025 * | 34.53B 4.92B | EV / Sales 2025 * | 4.22 x |
| P/E ratio 2024 * |
26.3
x | P/E ratio 2025 * |
20.6
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.87% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genmab
More recommendations
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Anders Pedersen
BRD | Director/Board Member | 73 | 03-10-31 |
Rolf K. Hoffmann
BRD | Director/Board Member | 63 | 15-12-31 |
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| -2.34% | 103B | |
| +2.31% | 96.56B | |
| +1.48% | 22.61B | |
| -16.72% | 21.18B | |
| -41.75% | 16.53B | |
| -23.26% | 14.46B | |
| -0.02% | 13.25B | |
| +22.69% | 11.1B | |
| -14.06% | 9.41B |
